Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2020-09-30 Regulatory Filings
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1886 characters) and contains the header 'RNS Number : 6350A'. It announces a 'Price Monitoring Extension' related to trading procedures on the London Stock Exchange. This is a brief, specific operational announcement disseminated via the RNS system, which is approved by the FCA to act as a Primary Information Provider. Since it is a general regulatory announcement that doesn't fit the specific categories like DIV, DIRS, or ER, the most appropriate classification is the general regulatory filing category.
2020-09-30 English
Launch of SARS-CoV-2 BAMS Research Test
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated September 30, 2020. It announces a specific corporate event: the launch of a SARS-CoV-2 research test developed with partners, including performance data published by Bruker. The text is structured as a formal news release, contains contact information for brokers and PR, and concludes with standard disclaimers about 'inside information' and RNS distribution services. This format is characteristic of a general regulatory announcement released via the London Stock Exchange's RNS system. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), the most appropriate classification is the general regulatory announcement category, RNS.
2020-09-30 English
Appointment of Joint Broker
Regulatory Filings Classification · 99% confidence The document is clearly identified as originating from 'RNS Number : 3503A' and contains boilerplate text referencing 'RNS, the news service of the London Stock Exchange' and 'Financial Conduct Authority'. The content announces a specific, non-financial event: the 'Appointment of Joint Broker'. This type of short, immediate corporate action announcement, distributed via the RNS system, fits best under the general Regulatory Filings category, as it is not a formal financial report (like 10-K, IR, ER) nor a specific management/director change (MANG) or dividend notice (DIV). It is a general regulatory announcement.
2020-09-29 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1886 characters) and contains the header 'RNS Number : 2803A'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange. This is a brief, specific regulatory announcement that does not fit into the major financial reporting categories (like 10-K, IR, ER). Since it is a direct announcement disseminated via the RNS system and concerns market operations rather than a specific financial result or corporate governance event, the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a fallback for miscellaneous regulatory notices.
2020-09-28 English
Interim Results for the Period Ended 30 June 2020
Earnings Release Classification · 99% confidence The document explicitly states: 'Avacta Group plc... is pleased to announce its unaudited interim results for the six-month period ended 30 June 2020.' This clearly identifies the document as a comprehensive financial report covering a period shorter than a full year (six months). This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). The presence of detailed financial highlights, operating highlights, and management commentary confirms it is a full report, not just a brief release (ER) or an announcement of a report (RPA). H1 2020
2020-09-28 English
Update on Integumen Collaboration
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 9402Z' and is dated '24 September 2020'. It contains an update on a collaboration ('Update on Integumen Collaboration') and includes contact information for brokers and PR firms, concluding with a disclaimer about 'Reach, the non-regulatory press release distribution service of RNS'. This structure is characteristic of a general regulatory news service announcement, which is the definition of RNS (Regulatory Filings). Since the content is a specific operational update rather than a formal financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or CAP), the most appropriate general category is RNS.
2020-09-24 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.